Pre-made Mipasetamab benchmark antibody ( Whole mAb, anti-AXL therapeutic antibody, Anti-ARK/UFO/JTK11/Tyro7 Antibody) for drug discovery and mechanism of action (MOA) research
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Pre-Made Mipasetamab biosimilar, Whole mAb, Anti-AXL Antibody: Anti-ARK/UFO/JTK11/Tyro7 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Mipasetamab Uzoptirine or ADCT-601 ia humanized antibody that binds to human AXL conjugated using Glycoconnect? technology to a linker with a PBD-dimer toxin. Once bound to an AXL-expressing cell, ADCT-601 is internalized into the cell, where enzymes release the PBD-based payload.
| Products Name (INN Index) | Pre-Made Mipasetamab biosimilar, Whole mAb, Anti-AXL Antibody: Anti-ARK/UFO/JTK11/Tyro7 therapeutic antibody |
|---|---|
| INN Name | Mipasetamab |
| Target | AXL |
| Format | Whole mAb |
| Derivation | NA |
| Species Reactivity | Human |
| CH1 Isotype | IgG1 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-I |
| Est. Status | Active |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2020 |
| Year Recommended | 2021 |
| Companies | ADC Therapeutics |
| Conditions Approved | NA |
| Conditions Active | Solid tumours,Advanced or metastatic solid tumours |
| Conditions Discontinued | NA |
| Development Tech | NA |
| Previous Name | NA |
| Gm Offical Target Name | AXL |
| Package |
